HC Wainwright & Co. Maintains Buy on Kronos Bio, Lowers Price Target to $2.25
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Kronos Bio (NASDAQ:KRON) but lowers the price target from $2.5 to $2.25.

May 03, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Kronos Bio's price target was reduced from $2.5 to $2.25 by HC Wainwright & Co., although the Buy rating was maintained.
The reduction in price target might cause some short-term negative sentiment among investors, but the maintenance of a Buy rating suggests underlying confidence in the company's fundamentals. This mixed signal could lead to neutral short-term price movement as the market digests both the reduced price target and the reaffirmed positive outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100